Weight loss · Once-daily tablet

Foundayo tablets for weight loss

Foundayo (orforglipron) is a prescription-only, once-daily tablet for weight management in adults, used alongside a reduced-calorie diet and more activity. Unlike other GLP-1 tablets, it can be taken at any time of day, with or without food.²

Check your eligibility →

CQC registered
UK-registered clinicians
Plain, discreet delivery

11.2%average weight loss at the highest dose over 72 weeks, vs 2.1% on placebo¹

Dailyone tablet, any time of day

All content on this page has been medically reviewed by Naeem Teni, Clinical Lead. GPhC 2215591.

What the trials showed

11.2%

average weight loss at the highest dose over 72 weeks, vs 2.1% on placebo¹

Average weight loss at 72 weeks

Placebo2.1%

5.5mg7.5%

9mg8.4%

17.2mg11.2%

ATTAIN-1, adults with obesity or overweight without diabetes. Doses shown as tablet strengths. Results vary from person to person.¹

Pricing

Pricing coming soon.

We're finalising prices for Foundayo. Your clinician confirms the cost before anything is prescribed.

How it works

What it does in the body.

A different kind of GLP-1
Orforglipron acts on the same GLP-1 receptor as semaglutide, but it's a small-molecule medicine rather than a peptide. That's why it doesn't need an empty stomach to be absorbed.¹
Hunger turns down
For many people that means less hunger between meals and feeling full sooner, so eating less takes less effort.
Digestion slows
It slows how quickly your stomach empties, so food stays with you longer.
Your changes do the rest
It supports changes to how you eat and move rather than replacing them, which is what helps results hold.

Once a day, whenever suits you.

Step 1

Pick a time

Any time of day works. Choose one you'll remember.²

Step 2

Food or no food

There's no need to fast or wait before eating.²

Step 3

Follow your plan

Your dose steps up over time. Don't change it without talking to your clinician.

Step 4

Keep it in the pack

Store tablets in their original packaging, as the leaflet explains.

Missed a dose? Check your leaflet or ask your clinician. Don't take two doses to make up for one.

Is it right for me?

Who it suits, and what to expect.

May be considered if

All of these usually apply

You're an adult, 18 or over, living in the UK.
Your BMI is 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes.
You're ready to use it alongside changes to how you eat and move.
A clinician judges it safe with your health history and medicines.

Not suitable if

Any one of these rules it out

You're pregnant, planning a pregnancy, or breastfeeding.
You have a history of medullary thyroid cancer or MEN 2.
You're allergic to orforglipron or any of its ingredients.
You have certain conditions, such as severe gastrointestinal disease.

Not sure where you fit? You don't need to work it out yourself. The assessment asks the right questions, and a clinician checks your answers.

Stomach-related side effects were the most common in trials. They tend to happen early on or after a dose increase, and ease with time.¹

More common

Usually mild, and often short-lived.

NauseaDiarrhoeaConstipationVomitingIndigestionStomach painHeadacheTiredness

Get help straight away if

These are rare, but need a doctor quickly.

Severe stomach pain that won't go away, sometimes reaching your back.
Pain in the upper right of your stomach, fever, or yellowing skin or eyes.
Vomiting or diarrhoea that stops you keeping fluids down.
Swelling of your face, lips or throat, or trouble breathing.

Pregnant or planning to be? Foundayo isn't for use in pregnancy. Tell your clinician if you're planning a family.

Your options

Two injections, two tablets.

Figures are average weight loss at the highest dose in each medicine's main trial, alongside diet and activity. They come from different trials in different people, so they aren't a direct ranking. The one direct comparison: when tirzepatide (Mounjaro) and injected semaglutide (Wegovy) were tested head to head over 72 weeks, average weight loss was 20.2% and 13.7%.⁶

This page

Foundayo

Orforglipron · Daily tablet11.2%over 72 weeks¹

Acts on GLP-1
Any time of day, with or without food

See pricing

Mounjaro

Tirzepatide · Weekly injection20.9%over 72 weeks³

Acts on GIP and GLP-1
Same day each week

£149 a month View →

Wegovy

Semaglutide · Weekly injection14.9%over 68 weeks⁴

Acts on GLP-1
Same day each week

£119 a month View →

Wegovy Pill

Semaglutide · Daily tablet13.6%over 64 weeks⁵

Acts on GLP-1
On an empty stomach with a sip of water, 30 minutes before food

£99 a month View →

Common questions

Foundayo, answered.

Is Manova a proper clinic, or a website?

Both. We’re a CQC-registered clinic that happens to live online. Every prescription is signed off by a registered clinician, not an algorithm.

Will it turn up in a branded box at my office?

No. Plain brown packaging, no Manova branding, no clue what’s inside. Sent to a home or pickup address, your call.

What if the clinician says no?

Then they say no, and you don’t get charged. They might suggest a safer alternative, more tests, or refer you back to your GP. We’d rather lose a customer than push the wrong pill.

Am I locked into a contract?

Nope. It’s month-to-month, cancel from your account in two clicks. No retention agent calling you back.

How is this different from going to my GP?

It isn’t, really same medicine, same regulator, same standards. We’re just faster to get hold of, and a lot less awkward to talk to about the things on this page.

Guides

Read up on Foundayo.

All Foundayo guides →

References (6)

Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806.
Foundayo (orforglipron) prescribing information and FDA approval announcement. Eli Lilly and Company, 2026.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.